We are live on ! Find out more
KURA icon

Kura Oncology

142 hedge funds and large institutions have $849M invested in Kura Oncology in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 51 increasing their positions, 53 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more call options, than puts

Call options by funds: $1.55M | Put options by funds: $755K

4% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 53

4% less funds holding

Funds holding: 148142 (-6)

4.25% less ownership

Funds ownership: 107%102.75% (-4.2%)

13% less capital invested

Capital invested by funds: $978M → $849M (-$128M)

19% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 21

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
142
Holders Change
-6
Holders Change %
-4.05%
% of All Funds
2.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
17
Increased
51
Reduced
53
Closed
21
Calls
$1.55M
Puts
$755K
Net Calls
+$791K
Net Calls Change
-$1.14M

KURA Hedge Fund Activity: Q4 2022 in Review

142 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2022, worth a combined $849M — down 13% from $978M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of KURA and 17 opened new positions — a net loss of 4 holders — while 53 trimmed existing stakes and 51 added.

The largest buyer was Suvretta Capital Management, adding an estimated $33.6M. The largest seller was Deep Track Capital, exiting entirely with an estimated $43.5M sold.

  • 142 institutional investors held Kura Oncology (KURA) as of Q4 2022, down from 148 in Q3 2022.
  • Funds reported $849M of Kura Oncology stock for Q4 2022, down 13% quarter-over-quarter.
  • 17 funds opened new Kura Oncology positions in Q4 2022 and 21 closed out, a net change of -4 holders.
  • The largest Kura Oncology buyer in Q4 2022 was Suvretta Capital Management, an estimated $33.6M added.
  • The largest Kura Oncology seller in Q4 2022 was Deep Track Capital, an estimated $43.5M sold.

Based on aggregated 13F filings for Q4 2022.